[HTML][HTML] Vivax malaria: neglected and not benign
Plasmodium vivax threatens almost 40% of the world's population, resulting in 132-391
million clinical infections each year. Most of these cases originate from South East Asia and …
million clinical infections each year. Most of these cases originate from South East Asia and …
[HTML][HTML] Artemisinin-based combination treatment of falciparum malaria
Artemisinin-based combination treatments (ACTs) are now generally accepted as the best
treatments for uncomplicated falciparum malaria. They are rapidly and reliably effective …
treatments for uncomplicated falciparum malaria. They are rapidly and reliably effective …
Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar
Background Plasmodium falciparum resistance to artemisinins, the first line treatment for
malaria worldwide, has been reported in western Cambodia. Resistance is characterized by …
malaria worldwide, has been reported in western Cambodia. Resistance is characterized by …
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment
Background Artemisinin combination treatments (ACT) are recommended as first line
treatment for falciparum malaria throughout the malaria affected world. We reviewed the …
treatment for falciparum malaria throughout the malaria affected world. We reviewed the …
[图书][B] Global report on antimalarial drug efficacy and drug resistance: 2000-2010
World Health Organization - 2010 - apps.who.int
BACkground Plasmodium resistance to antimalarial medicines is one of the major obstacles
in the fight against malaria. Comprehensive, up-to-date understanding of the scope of …
in the fight against malaria. Comprehensive, up-to-date understanding of the scope of …
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
A Ratcliff, H Siswantoro, E Kenangalem, R Maristela… - The Lancet, 2007 - thelancet.com
Summary Background The burden of Plasmodium vivax infections has been
underappreciated, especially in southeast Asia where chloroquine resistant strains have …
underappreciated, especially in southeast Asia where chloroquine resistant strains have …
Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian–Thai border
Artemisinin combination therapies (ACTs) have recently been adopted as first-line therapy
for Plasmodium falciparum infections in most malaria-endemic countries. In this study, we …
for Plasmodium falciparum infections in most malaria-endemic countries. In this study, we …
Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa
Background The efficacy of anti-malarial drugs is assessed over a period of 28-63 days
(depending on the drugs' residence time) following initiation of treatment in order to capture …
(depending on the drugs' residence time) following initiation of treatment in order to capture …
Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in …
A Mårtensson, J Strömberg, C Sisowath… - Clinical Infectious …, 2005 - academic.oup.com
Background. This is the first clinical trial comparing the efficacy of artesunate plus
amodiaquine (ASAQ) and artemether-lumefantrine (AL)—the major artemisinin-based …
amodiaquine (ASAQ) and artemether-lumefantrine (AL)—the major artemisinin-based …
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda …
P Piola, C Fogg, F Bajunirwe, S Biraro, F Grandesso… - The Lancet, 2005 - thelancet.com
Background The six-dose regimen of artemether-lumefantrine is effective and is among
combination therapies prioritised to replace antimalarials that no longer work in Africa …
combination therapies prioritised to replace antimalarials that no longer work in Africa …